AuroraCannabis stocks have been hammered in the market this year, with decreased profits and a growing black market to compete with. However, companies that adapt and diversify should be able to shake short-term worries, especially if they focus on international medical markets.

That’s exactly what Aurora Cannabis Inc. (NYSE: ACB) is doing, and this is good news for investors. Germany is the most promising international cannabis market today. Medical marijuana has been legalized since 2017, with imports peaking at 3,000 kilograms in 2018. Imports decreased to 2,500 kilograms this year, due to a lack of GMP-compliant cannabis that is required in the EU. Aurora has addressed this problem by investing in two new facilities that are GMP-certified. It should be able to increase production in 2020, with Germany becoming one of its major markets.

Aurora’s revenue has been growing at a phenomenal rate, despite the company missing profitability targets as it works on solidifying its business. In the company’s 2019 fiscal year, revenue was up 349%.

Aurora is affordable today, with stock price down -46.91% over the last 12-months. Investors can pick up this stock for a bargain with the long-term potential of increased revenues from the international medical cannabis industry.

Key Data:

  • 1 Year Price Growth: -46.91%
  • YTD Price Growth: -27.22%
  • 3 Month Price Growth: -42.24%

All information is based on current and historical market data, as well as publicly available financial data. As with any financial decision, your own research is important. Stock market outcomes can never be 100% accurately predicted. Familiarity with historical data, individual industries, and individual stocks is key to developing a robust portfolio. Note that stock prices can fluctuate rapidly during trading sessions.